Evidence map›Paper›PMID 40523922›Full record

ArticleBJC reports2025

The influence of clinical risk factors on the classification of human cancer-associated fibroblasts in PDAC and pancreatitis patients.

Viktoria Boeker, Lena Wilke, Ana Mansourkiaei, Van Manh H Le, Kaira A Church, Zoltan Czigany, Bo Kong, Fernanda G Kugeratski, Jörg Kleeff, Jürgen Weitz and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJC reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Viktoria BoekerDepartment of Visceral, Thoracic and Vascular Surgery, University Medical Center Carl Gustav Carus Dresden, Dresden, Germany. viktoria.boeker@uniklinikum-dresden.de.
Lena WilkeDepartment of Visceral, Thoracic and Vascular Surgery, University Medical Center Carl Gustav Carus Dresden, Dresden, Germany.
Ana MansourkiaeiDepartment of General-, Visceral-, and Transplant Surgery, Ruprecht Karl University Heidelberg, University Medical Center Heidelberg, Heidelberg, Germany.
Van Manh H LeDepartment of General-, Visceral-, and Transplant Surgery, Ruprecht Karl University Heidelberg, University Medical Center Heidelberg, Heidelberg, Germany.
Kaira A ChurchDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, USA.
Zoltan CziganyDepartment of General-, Visceral-, and Transplant Surgery, Ruprecht Karl University Heidelberg, University Medical Center Heidelberg, Heidelberg, Germany.
Bo KongDepartment of General-, Visceral-, and Transplant Surgery, Ruprecht Karl University Heidelberg, University Medical Center Heidelberg, Heidelberg, Germany.
Fernanda G KugeratskiDepartment of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA.
Jörg KleeffDepartment of Visceral, Vascular and Endocrine Surgery, Martin-Luther-University Halle-Wittenberg, University Medical Center Halle, Halle, Germany.
Jürgen WeitzDepartment of Visceral, Thoracic and Vascular Surgery, University Medical Center Carl Gustav Carus Dresden, Dresden, Germany.
Christoph KahlertDepartment of General-, Visceral-, and Transplant Surgery, Ruprecht Karl University Heidelberg, University Medical Center Heidelberg, Heidelberg, Germany. christoph.kahlert@med.uni-heidelberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer-associated fibroblasts (CAFs) constitute an important cell population in the microenvironment of pancreatic cancer. They can arise from disease-associated fibroblasts (DAFs) to support or restrain tumor growth. How many CAF subtypes exist and what signals drive their development is unclear. Currently, there are three commonly accepted subtypes, namely myofibroblast-like (myCAF), immunomodulatory (iCAF), and antigen-presenting (apCAF). Here, we analyzed the correlation between clinical risk factors with the proportion of each CAF subtype. In our patient cohort (n = 21), we investigated DAFs from patients with chronic pancreatitis (CP) and CAFs from pancreatic ductal adenocarcinoma (PDAC) patients after surgical resection via flow cytometry and RNA expression analysis. The expression of iCAF marker Interleukin-6 displayed significant differences depending on lifestyle factors, such as smoking status, age, and Body Mass Index (BMI). The apCAF marker HLA-DQA1 correlated with age. The largest difference showed the quantitative difference of apCAF markers in ~40% of PDAC- and ~20% of CP patients. In conclusion, clinical risk factors may influence the prevelance of specific CAF subsets. Unraveling the complex interplay between CAFs and tumor cells is crucial for novel therapies to improve long-term survival for pancreatic cancer patients.

Identifiers

PMID40523922
PMCPMC12170909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.